Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Combination therapy against vancomycin-resistant enterococci].

R Kariyama1, H Kumon

  • 1Department of Urology, Okayama University Medical School.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 18, 2001
PubMed
Summary

Vancomycin-resistant enterococci infections have limited treatment options. The combination of ampicillin and arbekacin shows promise for treating these difficult infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.

Cancer gene therapy·2016
Same author

Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.

Cancer gene therapy·2016
Same author

The induction of antigen-specific CTL by in situ Ad-REIC gene therapy.

Gene therapy·2016
Same author

Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma.

Gene therapy·2014
Same author

Clinical studies on advantages and safety of visual laser ablation for patients with benign prostatic hyperplasia.

International journal of urology : official journal of the Japanese Urological Association·2013
Same author

Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma.

Cancer gene therapy·2010

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Context:

  • Limited therapeutic options exist for vancomycin-resistant enterococci (VRE) infections.
  • Optimal treatment for serious enterococcal infections involves synergistic combinations of cell wall-active agents and aminoglycosides.
  • Increasing aminoglycoside resistance in enterococci compromises traditional therapeutic strategies.

Purpose:

  • To evaluate the efficacy of arbekacin, a novel semi-synthetic aminoglycoside, against resistant enterococci.
  • To assess the synergistic activity of ampicillin combined with arbekacin against vancomycin-resistant enterococci.

Summary:

  • Arbekacin exhibits potent activity against bacteria producing aminoglycoside-modifying enzymes, including those found in resistant enterococci.
  • The combination of ampicillin and arbekacin demonstrated significant inhibitory activity against vancomycin-resistant enterococci in recent studies.
  • This combination may offer a viable therapeutic option for treating challenging enterococcal infections.

Impact:

  • Provides a potential new therapeutic strategy for infections caused by multidrug-resistant enterococci.
  • Addresses the critical need for effective treatments against vancomycin-resistant enterococci.
  • May help mitigate the impact of antibiotic resistance on patient outcomes.

Related Experiment Videos